...
首页> 外文期刊>Medicine. >Tracheobronchial Stenoses in Granulomatosis With Polyangiitis (Wegener's) A Report on 26 Cases
【24h】

Tracheobronchial Stenoses in Granulomatosis With Polyangiitis (Wegener's) A Report on 26 Cases

机译:肉芽肿合并多血管炎(韦格纳氏)的气管支气管狭窄症26例报告

获取原文
获取原文并翻译 | 示例
           

摘要

Tracheobronchial stenoses (TBSs) are potentially severe manifestations of granulomatosis with polyangiitis (Wegener's) (GPA) that usually respond poorly to corticosteroids and immunosuppressive agents. We describe 26 GPA patients with 1 tracheal (mainly subglottic, SGS) and/or bronchial stenosis(ses) (BS(s)).Sixteen patients had solitary SGS and 10 had 1 BS(s). The male/female sex ratio was 9:17, and the median age at GPA diagnosis was 32 years (3:13 and 28 years, respectively, for SGS patients). Antineutrophil cytoplasm antibodies were proteinase 3-positive in 65.5% of the patients (50% of those with SGS).Despite conventional GPA therapy, 62% patients experienced 1 stenosis relapse(s) (81% of SGS patients, for a total of 1-8 relapses per patient). None of the several systemic or endoscopic treatments prevented future relapses. Cyclophosphamide induction therapy was effective in 4/6 patients with BS(s) and in 1 patient with SGS among the 7 treated. After many relapses, rituximab achieved remission in 3/4 SGS patients. Endoscopic treatments (dilation, laser, corticosteroid injection, etc.) had only transient efficacy. Other GPA manifestations relapsed independently of TBSs. One SGS patient died of acute respiratory distress syndrome.Our findings confirmed that TBSs are severe GPA manifestations that evolve independently of other organ involvements and do not respond to conventional systemic regimens. As previously described, our population was younger and comprised more females than usual GPA patients, especially those with SGS.The small number of patients and the wide variety of local and systemic treatments prevent us from drawing definitive conclusions about the contribution of each procedure. However, cyclophosphamide seemed to effectively treat BSs, but not SGS, and rituximab may be of interest for SGS management.
机译:气管支气管狭窄(TBS)可能是肉芽肿合并多血管炎(韦格纳氏病)(GPA)的潜在严重表现,通常对皮质类固醇和免疫抑制剂反应较差。我们描述了26例GPA患者,其中1例发生气管(主要是声门下,SGS)和/或支气管狭窄(ses).16例患有SGS,10例患有1 BS。男女性别比为9:17,诊断出GPA的中位年龄为32岁(SGS患者分别为3:13和28岁)。抗中性粒细胞胞浆抗体在65.5%的患者(50%患有SGS的患者)中呈3酶阳性。尽管采用常规GPA治疗,但62%的患者经历了1次狭窄复发(81%的SGS患者总计1每位患者-8次复发)。几种全身或内窥镜治疗均不能预防未来复发。环磷酰胺诱导疗法在7例接受治疗的4/6例BS患者和1例SGS患者中有效。多次复发后,利妥昔单抗在3/4 SGS患者中获得缓解。内窥镜治疗(扩张,激光,皮质类固醇注射等)仅具有短暂的疗效。其他GPA表现独立于TBS复发。一名SGS患者死于急性呼吸窘迫综合征。我们的研究结果证实TBS是严重的GPA表现,独立于其他器官的侵袭而发展,并且对常规全身疗法无反应。如前所述,与一般的GPA患者(尤其是SGS患者)相比,我们的人群更年轻,女性更多。患者数量少,局部和全身治疗的种类繁多,使我们无法就每种手术的作用得出明确的结论。但是,环磷酰胺似乎可以有效治疗BS,但不能有效治疗SGS,利妥昔单抗可能对SGS的治疗感兴趣。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号